English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduA potential drug successfully treats the severe form of nonalcoholic fatty liver disease in non-human primates — bringing scientists one step closer to the first human treatment for the condition that is rapidly increasing around the world, a study suggests. Nonalcoholic steatohepatitis (NASH) causes scarring and inflammation in the liver and is estimated to affect up to 6.5% of the global population.
Tag: Nonalcoholic Steatohepatitis
Novel Antisense Drug Shows Promise in Slowing Fatty Liver Disease
A first-in-class clinical trial suggests a novel treatment measurably slowed progression of non-alcoholic fatty liver disease to its more progressive and deadly form.
Too Much of a Good Thing May Lead to Too Much of a Liver As Well
UC San Diego researchers suggest that prolonged exposure to a pair of antioxidant proteins may contribute to enlargement of the liver and fatty liver diseases.